Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 1491 • 2018 ACR/ARHP Annual Meeting
Oestrogen Levels and the Outcome of Leflunomide Treatment in Rheumatoid Arthritis
Alaa A A Mohamed¹, Manal Hassanien¹ and Esraa A Ahmed², ¹Rheumatology and Rehabilitation, Faculty of Medicine, Assiut University Hospitals, Assiut, Egypt, ²Pharmacology, Faculty of Medicine, Assiut University, Assiut, Egypt
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune and inflammatory polyarthritis involving mainly the synovial joints, and causing destruction of the articular cartilage and disabilities. Leflunomide…
Abstract Number: 2454 • 2018 ACR/ARHP Annual Meeting
Virus Reactivation Rate in Rheumatoid Arthritis Using Tofacitinib
Yukitomo Urata, Rheumatology, Tsugaru General Hospital, United Municipalities of Tsugaru, Gosyogawara, Japan
Background/Purpose: Although the increase in the incidence of Herpes Zoster by tofacitinib(TOF) in rheumatoid arthritis (RA) is well known, the reactivation rate of other viruses…
Abstract Number: 24 • 2018 ACR/ARHP Annual Meeting
Rituximab Induces an Early Re-Assessment of the Immune and Vascular Systems in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Chary Lopez-Pedrera¹, Irene Cecchi², Nuria Barbarroja³, Alejandra Maria Patiño-Trives¹, María Luque Tevar¹, Laura Pérez Sánchez⁴, Alejandro Ibáñez-Costa¹, Ivan Arias de la Rosa⁵, Yolanda Jiménez-Gómez³, Massimo Radin⁶, Rafaela Ortega-Castro³, M. Carmen Castro-Villegas⁷, Jerusalem Calvo-Gutierrez³, Alejandro Escudero-Contreras⁵, Maria Jose Cuadrado⁸, Savino Sciascia⁹, Eduardo Collantes Estevez¹, Maria Ángeles Aguirre Zamorano¹ and Carlos Perez-Sanchez³, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ³Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁴IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁵Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁶Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁷Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁸Clinica Universidad de Navarra, Madrid, Spain, ⁹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy
Background/Purpose: While the role of Rituximab (RTX) in controlling the clinical manifestations of Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) has been documented, the…
Abstract Number: 578 • 2018 ACR/ARHP Annual Meeting
Effect of Disease Duration and Other Patient Baseline Characteristics on Outcomes in Tocilizumab-Treated Rheumatoid Arthritis Patients: A Pooled Analysis
Andrea Rubbert-Roth¹, Daniel Aletaha², Jenny Devenport³, Paris N. Sidiropoulos³, Yves Luder⁴, Michael Edwardes⁵ and Johannes W. G. Jacobs⁶, ¹Kantonsspital St Gallen, St Gallen, Switzerland, ²Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ³Genentech, Inc., South San Francisco, CA, ⁴F. Hoffmann-La Roche, Basel, Switzerland, ⁵Everest Clinical Research, Markham, ON, Canada, ⁶Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands, Utrecht, Netherlands
Background/Purpose: Tocilizumab (TCZ) efficacy and safety in rheumatoid arthritis (RA) have been well established by numerous phase 3 and 4 studies and observational studies. The…
Abstract Number: 1495 • 2018 ACR/ARHP Annual Meeting
Baseline Characteristics of Methotrexate Inadequate Responder Patients with RA Who Achieved Low Disease Activity with Tofacitinib Monotherapy
Jeffrey Kaine¹, Alan J. Kivitz², Eduardo Mysler³, Noriko Iikuni⁴, Haiyun Fan⁵, Annette Diehl⁵, Jerome Paulissen⁶ and Christopher W Murray⁵, ¹Sarasota Arthritis Research Center, Sarasota, FL, ²Altoona Center for Clinical Research, Duncansville, PA, ³Organización Médica de Investigación, Buenos Aires, Argentina, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Collegeville, PA, ⁶Syneos Health, Raleigh, NC
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. ORAL Strategy (NCT02187055) was a Phase 3b/4, 1-year, double-blind, triple-dummy, active comparator-controlled…
Abstract Number: 2456 • 2018 ACR/ARHP Annual Meeting
Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients in Truven Marketscan Data (Jan 2010–Sept 2015) Treated with Biologic or Conventional Dmards
Claudia A. Salinas¹, Lucy Mitchell², Jon T. Giles³, Thomas Dörner⁴ and Stephen P. Motsko¹, ¹Eli Lilly and Company, Indianapolis, IN, ²Eli Lilly and Company, Indianapols, IN, ³Columbia University, College of Physicians and Surgeons, New York, NY, ⁴Charité Universitätsmedizin Berlin and Deutsches Rheuma-Forschungszentrum (DRFZ), Berlin, Germany
Background/Purpose: Patients with RA have an increased risk of venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT) compared to non-RA populations1. …
Abstract Number: 43 • 2018 ACR/ARHP Annual Meeting
Novel Anti-Malarial Drug Derivative Inhibited Anti-Citrullinated Protein/Peptide Antibodies and Rheumatoid Factors Production in Dnaseii/Ifnr Double Knock out Mice
Jie An¹, Bhanupriya Madarampalli², Xizhang Sun², Lena Tanaka³, Erika H. Noss², Joshua Woodward⁴, Tomikazu Sasaki⁵ and Keith B. Elkon⁶, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Rheumatology, University of Washington, Seattle, WA, ³Medicine/Rheumatology, University of Washington, Seattle, WA, ⁴Department of Microbiology, University of Washington, Seattle, WA, ⁵Department of Chemistry, University of Washington, Seattle, WA, ⁶University of Washington, Seattle, WA
Background/Purpose: Rheumatoid Arthritis (RA) is a highly prevalent autoimmune disease affecting ~1% of the world population and can lead to permanent joint damage and severe…
Abstract Number: 582 • 2018 ACR/ARHP Annual Meeting
Baseline Power Doppler and Multi-Biomarker Disease Activity Score Predict 12-Week Disease Activity Response to Tofacitinib
Amir Razmjou¹, Jenny Brook², Gurjit Kaeley³, David Elashoff² and Veena K. Ranganath⁴, ¹Internal Medicine, UCLA-David Geffen School of Medicine, Los Angeles, CA, ²Department of Medicine Statistics Core, UCLA David Geffen School of Medicine, Los Angeles, CA, ³UF Health Jacksonville, Jacksonville, FL, ⁴1000 VETERAN BLVD., RM 32-59, UCLA, Los Angeles, CA
Background/Purpose: Point of care tailored treatment strategies are of value to improve rheumatoid arthritis (RA) patient outcomes. Musculoskeletal ultrasound (MSUS) is increasingly used as a…
Abstract Number: 1523 • 2018 ACR/ARHP Annual Meeting
Pain Is Improved in Around 50% of Patients and Fatigue in 40% of Patients with Rheumatoid Arthritis Treated with Sarilumab in the Target, Mobility and Monarch Trials
Laure Gossec^1,2, Susan Boklage³, Gregory St. John³, Hubert van Hoogstraten⁴ and Toshio Kimura³, ¹Sorbonne Universités, Paris, France, ²Stanford University, Palo Alto, CA, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Sanofi Genzyme, Bridgewater, NJ
Background/Purpose: Pain and fatigue are common symptoms of rheumatoid arthritis (RA) and can severely impact patients’ quality of life. With multiple biologic disease-modifying antirheumatic drugs…
Abstract Number: 2458 • 2018 ACR/ARHP Annual Meeting
Predictors of Hypogammaglobulinemia during Rituximab Maintenance Therapy in Rheumatoid Arthritis: A 12-Year Longitudinal Multi-Center Study
Gonçalo Boleto¹, Jérôme Avouac¹, Julien Wipff¹, Marine Forien², Maxime Dougados³, Christian Roux⁴, André Kahan¹, Philippe Dieude² and Yannick Allanore¹, ¹Université Paris Descartes, Sorbonne Paris Cité, Service de Rhumatologie A, Hôpital Cochin, Paris, France, Paris, France, ²Université Paris Diderot, Service de Rhumatologie, Hôpital Bichat, APHP, Paris, France, Paris, France, ³Department of Rheumatology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris Descartes University, Paris, France, Paris, France, ⁴Université Paris Descartes, Sorbonne Paris Cité, INSERM U1153, Service de Rhumatologie B, Hôpital Cochin, Paris, Paris, France
Background/Purpose: Rituximab (RTX) is an anti-CD20 monoclonal antibody that selectively depletes B-cell population. Thus, it presents a potential risk for the development of hypogammaglobulinemia and…
Abstract Number: 64 • 2018 ACR/ARHP Annual Meeting
Dietary Magnesium Modulates the Intestinal Microbiome and T Cell Subsets
Teresina Laragione¹, Carolyn Harris¹ and Percio S. Gulko², ¹Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY, ²Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Several studies have demonstrated that Magnesium (Mg) has a key role in the immune responses. Our previous studies showed that a short-term low Mg…
Abstract Number: 596 • 2018 ACR/ARHP Annual Meeting
Combination of Intra-Articular Steroid Injection and Tofacitinib More Effective Than Tofacitinib in Rapid Radiographic Progression Patients with Rheumatoid Arthritis
Kensuke Kume¹, Kanzo Amano¹, Susumu Yamada², Toshikatsu Kanazawa² and Kazuhiko Hatta³, ¹Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ²rheumatology, hiroshima clinic, hiroshima, Japan, ³Rheumatology, Hatta Clinic, Kure, Japan
Background/Purpose: Treatment of rheumatoid arthritis (RA) should aim at full remission. However, we experienced that rapid radiographic progression (RRP) existed despite initial tofacitinib and methotrexate…
Abstract Number: 1537 • 2018 ACR/ARHP Annual Meeting
Frequency and Duration of Early Non-Serious Adverse Events in Rheumatoid Arthritis Patients Treated with Tofacitinib 5 Mg Twice Daily As Monotherapy and Combination Therapy
Ara Dikranian¹, Jürgen Wollenhaupt², Valderilio F Azevedo³, Louis Bessette⁴, David Gold⁵, Jose L Rivas⁶, Harry Shi⁷, Lisy Wang⁸, John Woolcott⁷, Andrea Shapiro⁹ and Peter Nash¹⁰, ¹Cabrillo Center for Rheumatic Disease, San Diego, CA, ²Schön Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ³Universidade Federal do Paraná, Curitiba, Brazil, ⁴Laval University, Kirkland, QC, Canada, ⁵Pfizer Canada, Montreal, QC, Canada, ⁶Pfizer SLU, Madrid, Spain, ⁷Pfizer Inc, Collegeville, PA, ⁸Pfizer Inc, Groton, CT, ⁹Pfizer Inc, Peapack, NJ, ¹⁰University of Queensland, Brisbane, Australia
Background/Purpose: Tolerability remains ill-defined in clinical trials and most commonly refers to non-serious adverse events (AEs) that may impact patient (pt) satisfaction and adherence to…
Abstract Number: 2462 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety in the Middle-LONG Period of Rituximab in the Treatment of Diffuse Interstitial Pulmonary Disease Associated with Rheumatoid Arthritis
Francisco Javier Narváez¹, Alejandro Robles Perez², Patricio Luburich³, J Alegre⁴, Milagros Ricse⁵, Carmen Gomez Vaquero⁶, Joan Miquel Nolla⁵ and Maria Molina⁵, ¹Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ²Pneumology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Radiology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Rheumatology, Hospital Universitario Doctor Peset. Valencia. Spain, Valencia, Spain, ⁵Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Rheumatology Department, Hospital Universitario de Bellvitge, Idibell, Barcelona, Spain
Background/Purpose: To evaluate the efficacy and safety of rituximab (RTX) in the medium- to long-term for the management of progressive rheumatoid arthritis–related interstitial lung disease…
Abstract Number: 75 • 2018 ACR/ARHP Annual Meeting
Elevated Oxylipin Profile in Autoantibody-Positive Individuals at-Risk of Developing Rheumatoid Arthritis
Vidyanand Anaparti¹, Irene Smolik², Tanja Winter³, Xiaobo Meng⁴, Harold Aukema³ and Hani El-Gabalawy⁴, ¹Internal Medicine, University of Manitoba, Winnipeg, MB, Canada, ²Arthritis Center, University of Manitoba, Winnipeg, MB, Canada, ³Food and Nutritional Sciences, University of Manitoba, Winnipeg, MB, Canada, ⁴University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Preclinical phase of rheumatoid arthritis (RA) is characterized by presence of autoantibodies, including anti-citrullinated protein antibodies (ACPA), years before disease onset. Epidemiological observations suggest…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].